Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme) by biopsy or resection within the past 3 months~PATIENT CHARACTERISTICS:~* Karnofsky performance status ≥ 60%~* Absolute neutrophil count ≥ 1500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Bilirubin ≤ 1.5 mg/dL~* Transaminases ≤ 4 times above the upper limits of the institutional normal~* Creatinine ≤ 1.7 mg/dL~* Not pregnant or breast-feeding~* Patients must agree to follow acceptable birth control methods to avoid conception~* Negative pregnancy test~* Patients must have a Mini Mental State Exam score of ≥ 15~* No serious concurrent infection or medical illness which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety~* Patients with a concurrent or prior malignancy are ineligible unless they are patients with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin~  * Patients who have been free of disease (any prior malignancy) for ≥ five years are eligible for this study~* Patients requiring ongoing therapy for psychoses with antipsychotic medications at the time of enrollment will be ineligible~PRIOR CONCURRENT THERAPY:~* Patients must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor~  * Prior glucocorticoid therapy is allowed~* Patients must be willing to forego other cytotoxic and non-cytotoxic drug therapy against the tumor while being treated with poly ICLC plus temozolomide on this protocol~* No other concurrent therapy for their tumor (i.e., chemotherapeutics or investigational agents)~* Patients who have received prior Gliadel wafers are not eligible for this study~* No concurrent prophylactic filgrastim (G-CSF)~* No concurrent electron, particle, implant, or stereotactic radiosurgery boost

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): RT + TMZ 6wks, followed by~poly ICLC, temozolomide, radiation: radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).